KDOQI对美国2017年ACC/AHA高血压指南的解读
KDOQI发布对美国2017年ACC/AHA高血压指南的解读,聚焦慢性肾脏病(CKD)或CKD风险人群的血压目标与管理策略,并简要讨论欧洲关于透析患者高血压诊疗的共识声明。总体支持ACC/AHA绝大多数推荐,并指出诊断与治疗仍存争议的领域。
要点
- KDOQI支持ACC/AHA高血压指南绝大多数推荐适用于CKD人群。
- ACC/AHA指南未涉及透析患者的血压目标与管理策略。
- 该解读指出CKD患者最佳诊断与治疗选项仍存争议。
核心结论
- KDOQI总体支持ACC/AHA高血压指南的绝大多数推荐。
- 该解读聚焦CKD或CKD风险人群,并指出最佳诊疗仍存争议领域。
研究设计与样本
- KDOQI对2017年ACC/AHA高血压指南的解读,基于系统综述与观察性数据。
主要发现
- ACC/AHA指南未讨论透析患者的血压目标与管理策略。
- 解读简要讨论了ERA-EDTA与ESH关于维持性透析成人高血压诊疗的共识声明。
临床怎么用
- 临床可参照ACC/AHA推荐管理CKD或CKD风险患者的高血压。
- 透析患者血压管理需参考欧洲共识声明。
局限性
- ACC/AHA指南未涵盖透析患者血压目标与管理策略。
- CKD患者最佳诊断与治疗选项仍存争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypertension is a modifiable risk factor for cardiovascular morbidity and mortality and reduction of elevated blood pressure (BP) remains an important intervention for slowing kidney disease progression. Over the past decade, the most appropriate BP target for initiation and titration of BP-lowering medications has been an area of intense research and debate within the clinical community. In 2017, the American College of Cardiology and the American Heart Association (ACC/AHA) in conjunction with several other professional societies released new hypertension guidelines based on data from a systematic review of clinical trials and observational data. While many of the recommendations in the ACC/AHA hypertension guideline are relevant to nephrology practice, BP targets and management strategies for patients receiving dialysis are not discussed. This Kidney Disease Outcomes Quality Initiative (KDOQI) commentary focuses largely on recommendations from the ACC/AHA hypertension guidelines that are pertinent to individuals at risk of chronic kidney disease or with non-dialysis-dependent chronic kidney disease. This KDOQI commentary also includes a brief discussion of the consensus statement regarding hypertension diagnosis and management for adults receiving maintenance dialysis published by the European Renal and Cardiovascular Medicine Working Group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension. Overall, we support the vast majority of the ACC/AHA recommendations and highlight select areas in which best diagnosis and treatment options remain controversial.
引用
- Kramer HJ, Townsend RR, Griffin K, et al. KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. Am J Kidney Dis. 2019. PMID: 30905361. doi:10.1053/j.ajkd.2019.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。